Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Fruquintinib + paclitaxel
- Development stage
- Unknown
- Lead developer
- HUTCHMED
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
Fruquintinib + paclitaxel is a combination therapy evaluated for the treatment of advanced gastric or gastroesophageal junction adenocarcinoma, particularly as a second-line option. Fruquintinib is an oral, highly selective small-molecule inhibitor of vascular endothelial growth factor receptors (VEGFR) 1, 2, and 3. By blocking these receptors, fruquintinib inhibits tumor angiogenesis—the process by which tumors develop new blood vessels to support their growth and metastasis[3][4][6][8]. Paclitaxel is a well-established chemotherapeutic agent that stabilizes microtubules and prevents cell division. The combination has demonstrated improved progression-free survival compared to paclitaxel alone in phase III clinical trials for patients with previously treated advanced gastric cancer[1][2][3][8]. Fruquintinib was developed by HUTCHMED and marketed under the brand name Fruzaqla; it has been approved for metastatic colorectal cancer in several regions.
- Other names
- None
02
Targets
VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)TUBB (Tubulin (alpha and beta subunits))VEGFR2 (Vascular endothelial growth factor receptor 2)
Beyond the preview
Go deeper on Fruquintinib + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Fruquintinib + paclitaxel.